厄洛替尼治疗19例晚期非小细胞肺癌的临床观察  

Clinical Observation for 19 Cases of Advanced Non-small-cell Lung Cancer Treated with Erlotinib

作　　者：刘梅[1,2] 张幸平[1] 甘露[1] 张涛[1] 戴晓波[1] 徐舒曼[1] 

机构地区：[1]重庆医科大学附属第一医院肿瘤科,重庆400016 [2]襄阳市中心医院肿瘤科,湖北襄阳441021

出　　处：《现代生物医学进展》2016年第20期3876-3879,3921,共5页Progress in Modern Biomedicine

基　　金：国家临床重点专科建设项目经费资助(国卫办医函[2013]544号)

摘　　要：目的:观察厄洛替尼(Erlotinib)治疗晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)的临床疗效及毒副反应。方法:我科于2011年2月-2014年2月收治19例晚期NSCLC患者,给予口服Erlotinib 150 mg/天进行分子靶向治疗,直至疾病进展或出现不可耐受的毒副反应,对其临床疗效及毒副反应进行观察。结果:19例患者均可进行疗效评估,客观缓解率为21.1%(4/19),疾病控制率为63.2%(12/19)。中位无进展生存期为8个月(95%CI 5.5-10.8),中位生存期为17个月(95%CI 11.3-22.7),1年生存率为73.7%(14/19),2年生存率为45.5%(5/11)。分析发现患者的性别、年龄、病理类型、吸烟史、手术史、放疗史与客观缓解率、疾病控制率无明显相关性(P>0.05),仅化疗史与疾病控制率相关(P=0.02)。Erlotinib的副反应较轻,无患者因毒副反应而减量或停药。结论:Erlotinib治疗晚期NSCLC的疗效及安全性良好,可作为不能耐受放化疗或放化疗失败的晚期NSCLC患者的治疗选择。Objective： To observe the efficacy and adverse events of Erlotinib in treatment of advanced non-small-cell lung cancer （NSCLC）. Methods： From February 2011 to February 2014,19 cases of advanced NSCLC patients were treated with Erlotinib orally, at a dose of 150 mg per day till disease progression or intolerable adverse events. The efficacy and adverse events of Erlotinib was detected. Results： Among 19 evaluable cases, the objective response rate（ORR）was 21.1% （4/19） and the disease control rate（DCR）was 63.2 % （12/19）. The median progression free survival （PFS）was 8 months, and the median overall survival （OS） was 17 months. 1-year survival rate was 73.7%（14/19）, 2-year survival rate was 45.5%（5/11 ）. Analysis showed that gender, age, pathological type, smoking history, surgery, radiotherapy had little correlation on the objective response rate, disease control rate （P 〉0.05）. Only chemotherapy was associated with disease control rate （P=0.02）. The side -effect of Edotinib was mild, no dose reduction or withdrawal of drugs in all the patients due to adverse reaction. Conclusions： Erlotinib is effective and safety for advanced NSCLC, it is a good choice for advanced NSCLC patients who can not tolerate chemoradiotherapy or chemoradiotherapy failure.

关 键 词：非小细胞肺癌 分子靶向治疗 表皮生长因子受体 酪氨酸激酶抑制剂 厄洛替尼 

分 类 号：R734.2[医药卫生—肿瘤]